14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMRA vs TCMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas TCMD carries 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin).
Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY).
Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Devices value chain with $601.1M market capitalization and 9.4% operating margin.
OpEx & R&D Reinvestment67.6% of Rev ($241M)
90D Engineering Disclosures0 Published
Investor FAQ BMRA vs TCMD Key Questions & Quantitative Answers
As of Nov 16, 2026, Tactile Systems Technology, Inc. (TCMD) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas TCMD carries 25.0/100 (SELL) at $26.36 (18.2x Forward P/E, 9.4% operating margin). Composite vs. Pillar Nuance: While BMRA currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. TCMD 25.0/100 SELL), TCMD captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (9.4% vs. -125.2% operating margin) and revenue trajectory (+7.1% vs. -8.3% YoY). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile TCMD trades in a Markup technical trend (CONSOLIDATION options phase, RSI 60.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TCMD leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with TCMD at +7.1% YoY revenue growth and -13.9% YoY earnings growth on $356M TTM revenue (77.0% gross margin, 9.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while TCMD shifted +73.7%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus 67.6% of Rev ($241M) (0 disclosures) for TCMD.
TCMD screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas TCMD trades at 18.2x Forward P/E, 26.1x Trailing P/E, 17.79x PEG, and 1.5x EV/Revenue (8.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus TCMD (11.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, TCMD carries 54.9% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 53% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.